Quidel appoints Mason CEO
This article was originally published in The Gray Sheet
Executive Summary
Caren Mason assumes beleaguered point-of-care rapid diagnostic test firm's top spot Aug. 20, replacing Wayne Kay (1"The Gray Sheet" July 19, 2004, p. 24). Mason brings over 25 years of healthcare experience to the Quidel post, ranging from service as CEO of two digital technology start-ups, eMed Technologies and MiraMedica, to running GE Medical Systems' Women's Healthcare business. Initially, she plans to focus on building Quidel R&D initiatives and solidifying relationships with end-users...
You may also be interested in...
People In Brief
Alcon President & CEO: Cary Rayment plans to build Alcon's international surgical and pharmaceutical businesses in Asia after assuming the joint position Oct. 1. He will seek further expansion into Japan, the firm's second largest market behind the U.S., as well as China, Korea and India. Rayment, 57, will replace Tim Sear, 67, who has been with Alcon 34 years and saw the firm through its 2002 initial public offering. In 2001, Rayment became senior-VP, directing cross-divisional efforts for surgical, pharmaceutical and consumer groups in the U.S. In January, he took responsibility for Alcon Japan. Rayment has been with Alcon since it acquired CooperVision Surgical in 1989. Kevin Buehler, 47, a 20-year Alcon veteran and VP-operations, Latin America, Canada and the Far East, will replace Rayment...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.